Xilio Therapeutics (XLO) Gains from Investment Securities (2020 - 2026)

Xilio Therapeutics has disclosed Gains from Investment Securities across 7 years of filings, most recently posting -$3.3 million for Q1 2026.

• Gains from Investment Securities for Q1 2026 came in at -$3.3 million, down 1130.67% year-over-year; the trailing twelve-month figure through Mar 2026 was -$24.5 million (down 7759.75% YoY), and the FY2025 annual result was $2.8 million, up 368.03% from the prior year.
• Gains from Investment Securities came in at -$3.3 million for Q1 2026 at Xilio Therapeutics, up from -$21.3 million in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $5.0 million in Q3 2022 to a low of -$21.3 million in Q4 2025.
• The 5-year median for Gains from Investment Securities is $450708.0 (2023), against an average of -$463960.7.
• Across the five-year window, Gains from Investment Securities jumped 6389.6% in 2022 and sank 1130.67% in 2026, its largest moves.
• Xilio Therapeutics' Gains from Investment Securities stood at $21000.0 in 2022, then changed by 0.0% to $21000.0 in 2023, then jumped by 7176.49% to $1.5 million in 2024, then slumped by 1492.29% to -$21.3 million in 2025, then jumped by 84.49% to -$3.3 million in 2026.
• The last three Gains from Investment Securities figures came in at -$3.3 million (Q1 2026), -$21.3 million (Q4 2025), and $686036.0 (Q3 2025), per Business Quant data.